HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Galderma S.A.

http://www.galderma.com

Latest From Galderma S.A.

Financing Quarterly Statistics, Q2 2022

During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.

Deals Financing

Minute Insight: Lumos’ Bacterial-Viral Infection Differentiation Test Flops At FDA

Lumos Diagnostics is considering an appeal of the agency’s decision to refuse market clearance for its FebriDX test.

Regulation In Vitro Diagnostics

Galderma Hopes To Break Into Prurigo Nodularis Market, But May Face Rivals

The dermatology specialist announced positive results from the OLYMPIA 2 trial of nemolizumab, but Sanofi and Regeneron are already pursuing a similar indication for Dupixent. 

Clinical Trials Business Strategies

Bigger Money: Private Equity Grabs European VC

Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?

Business Strategies Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Alastin Skincare, Inc.
    • CollaGenex Pharmaceuticals, Inc., Nestle S.A.
    • Nestle Skin Health S.A.
    • Spirig Pharma AG
    • Q-Med AB
UsernamePublicRestriction

Register